Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026169 | 0.90 | PARP1 (0.54) | KDM4CPARP1POLBKDM4ENPC1 | |
| SCHEMBL4361327 | 0.86 | DDAH1 (0.55) | POLBDDAH1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL10514181 | 0.83 | MAPT (0.37) | PARP1POLBDDAH1SMN1; SMN2 | |
| SCHEMBL13233304 | 0.82 | CYP1A2 (0.43) | POLBDDAH1PDE10ASMN1; SMN2NPC1 | |
| SCHEMBL7002587 | 0.82 | GAA (0.42) | POLBDDAH1SMN1; SMN2NPC1LMNA | |
| SCHEMBL15924586 | 0.80 | PARP1 (0.42) | PARP1POLB | |
| SCHEMBL7823286 | 0.80 | RAD52 (0.46) | PARP1POLBNPC1LMNARAB9A | |
| SCHEMBL6948812 | 0.79 | PKM (0.58) | POLBDDAH1SMN1; SMN2NPC1LMNA | |
| SCHEMBL31660973 | 0.79 | CYP1A2 (0.37) | PARP1POLBPDE10ASMN1; SMN2NPC1 | |
| SCHEMBL18291869 | 0.79 | ALDH1A1 (0.38) | PARP1POLBDDAH1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3038622-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2740730-B1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
| US-8969345-B2 | Dibenzooxepin derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| EP-2740730-A1 | DIBENZOOXEPIN DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-06-11 | — | — | EP | disclosed |
| EP-0415886-A2 | Aza compounds | CIBA-GEIGY AG (CH) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRAS, VHL, ESRRB | KDM4C 3165/4885PARP1 1465/4885POLB 804/4885 |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | KDM4C 1625/4885PARP1 2854/4885POLB 2603/4885 |
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | PPARA, PPARG, PPARD | KDM4C 2374/4885PARP1 3969/4885POLB 3377/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | KDM4C 3165/4885PARP1 1465/4885POLB 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.